Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
23.4M
-
Shares change
-
+174K
-
Total reported value, excl. options
-
$165M
-
Value change
-
+$1.23M
-
Number of buys
-
34
-
Number of sells
-
-36
-
Price
-
$7.06
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2020
84 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q1 2020.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.4M shares
of 62.2M outstanding shares and own 37.6% of the company stock.
Largest 10 shareholders include FMR LLC (4.09M shares), RTW INVESTMENTS, LP (2.66M shares), Johnson & Johnson Innovation - JJDC, Inc. (2.45M shares), BAKER BROS. ADVISORS LP (1.68M shares), BlackRock Inc. (1.56M shares), FARALLON CAPITAL MANAGEMENT LLC (1.5M shares), VANGUARD GROUP INC (991K shares), JPMORGAN CHASE & CO (883K shares), Novo Holdings A/S (698K shares), and BVF INC/IL (692K shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.